1. Medtech Insight
  2. >>Business

Libre 3 Sensors: With Second Plant Online, Abbott Aims For Under-Penetrated ‘Intensive Insulin’ Segment

International sales could be a key driver as firm also looks to partnerships with insulin pump companies.

 
• By Shubham Singh

Abbott’s international sales could be a key driver as firm looks to partnerships with insulin pump companies.

Despite previous supply challenges, Abbott said in its earnings call that it continues to report robust growth in the continuous glucose monitoring (CGM) market. (Shutterstock)
Key Takeaways
  • Abbott launched a new 323,000-square-foot manufacturing facility in Kilkenny, Ireland, employing more than 800 people to ramp up FreeStyle Libre 3 sensor production. 

    With the launch of its second manufacturing plant, Abbott is ramping up production of its FreeStyle Libre 3 sensors, aiming to expand its reach in the under-penetrated intensive insulin-using segment....

    More from Business

    More from Device Area